



1



2



3

ADRENERGIC RECEPTORS

Def.: Adrenoceptors are membrane-bound receptors coupled with G proteins, specific to adrenaline, noradrenaline & their antagonists.

Location:

- CNS (central),
- Nerve endings (presynaptic),
- Effector organs (postsynaptic).

Types:

- Alpha (α):**
 - α₁
 - α₂
- Beta (β):**
 - β₁
 - β₂
 - β₃

4

ADRENERGIC RECEPTORS

α_1 receptor

Sites: Mainly effector organs (postsynaptic).


Mechanism: G_q -Protein \rightarrow \uparrow PLC \rightarrow \uparrow IP₃ & DAG \rightarrow \uparrow Ca²⁺ \rightarrow response

Actions: (Fight and fright)

- Contraction of pilomotor muscle \rightarrow erection of hair
- Contraction of dilator pupillae muscle \rightarrow active mydriasis
- Generalized vasoconstriction \rightarrow \uparrow TPR \rightarrow \uparrow Bl. Pr.
- Viscid salivation
- Spasm in sphincters of GIT and UB
- Ejaculation & contraction of prostatic capsule
- Contraction of pregnant uterus

Selective agonist: phenylephrine

Selective antagonist: prazosin



5

ADRENERGIC RECEPTORS

α_2 receptor

Sites: Central; presynaptic; postsynaptic.


Mechanism: G_i -Protein \rightarrow \downarrow AC \rightarrow \downarrow cAMP \rightarrow \downarrow Ca²⁺ \rightarrow response

Actions: (Calming)

- \downarrow CNS \rightarrow sedation & \downarrow sympathetic centers.
- Presynaptic:
 - \downarrow release of NA
 - \downarrow ACh in enteric ganglia \rightarrow relaxation of GIT
- Kidney: \downarrow release of renin \rightarrow \downarrow Bl. Pr.
- Pancreas: \downarrow release of insulin
- Adipose tissue: \downarrow lipolysis \rightarrow \downarrow Bl. F.F.A.

Selective agonist: clonidine

Selective antagonist: yohimbine



6

ADRENERGIC RECEPTORS


β_1 receptor

Sites: Central; postsynaptic.

Mechanism: G_s -Protein \rightarrow \uparrow AC \rightarrow \uparrow cAMP \rightarrow Protein kinase-A + open Calcium Channel \rightarrow \uparrow Ca⁺⁺ \rightarrow \uparrow response

Actions: (Alertness)

- \uparrow CNS \rightarrow anxiety
- \uparrow heart \rightarrow \uparrow Cardiac output
- Kidney: \uparrow renin
- Adipose tissue: \uparrow lipolysis



Selective agonist: dobutamine

Selective antagonist: atenolol

7

ADRENERGIC RECEPTORS


β_2 receptor

Sites: Central; presynaptic; postsynaptic.

Mechanism: G_s -Protein \rightarrow \uparrow AC \rightarrow \uparrow cAMP \rightarrow \downarrow Myosin light chain kinase in SM. muscle, Bl.Vs, Bronchi, UB, Uterus \rightarrow relaxation

Actions: (For muscle)

- Generalized VD especially for Sk. muscles
- Bronchodilation
- Uterus, UB & GIT walls: relaxation
- \uparrow glycogenolysis in liver & Sk. Muscles
- \uparrow release of insulin



Selective agonist: salbutamol

Selective antagonist: butoxamine

8

ADRENERGIC RECEPTORS

β_3 receptor

Sites: Postsynaptic, mainly in adipose tissue.

Mechanism: G_s -Protein \rightarrow \uparrow AC \rightarrow \uparrow cAMP

Actions: (For catabolism)

- \uparrow lipolysis

- \uparrow thermogenesis

Selective agonist: octopamine

Selective antagonist: ---



9

CLASSIFICATION OF SYMPATHETIC DRUGS

SYMPATHOMIMETICS

(drugs which stimulate adrenergic receptors & neurons and produce actions similar to those of sympathetic nerve stimulation)

SYMPATHOLYTICS

(drugs which block adrenergic receptors & neurons and produce actions similar to those of sympathetic nerve inhibition)

SYMPATHOMIMETICS

A. According to nature:

Natural (in the body):

As adrenaline, noradrenaline & dopamine

Synthetic:

As ephedrine, amphetamine, isoprenaline, ...




10

B. According to chemical structure:

- **Catecholamines:**
 - Have catechol nucleus
 - As adrenaline, noradrenaline, isoprenaline, dopamine, dobutamine, hexoprenaline, α -methyl noradrenaline, ...
- **Non-catecholamines:**
 - Do not have catechol nucleus
 - As ephedrine, amphetamine, ...

C. According to mechanism of action:


- **Direct stimulation of adrenoceptors:**
As adrenaline, noradrenaline, isoprenaline,...
- **Indirect by:**
 - Release of NA as amphetamine
 - Inhibiting uptake-1 of NA as reboxetine
 - Inhibiting MAO as phenelzine
 - Inhibiting COMT as entacapone
- **Dual or mixed mechanism (direct + indirect):**
As ephedrine



11

D. According to receptor selectivity:

- **α -receptor agonists:**
 - Selective α_1 agonists: as phenylephrine & methoxamine
 - Selective α_2 agonists: as clonidine & α -methyl NA
 - Non-selective $\alpha_1 + \alpha_2$ agonists: as oxymetazoline
- **β -receptor agonists:**
 - Selective β_1 agonists: as dobutamine
 - Selective β_2 agonists: as salbutamol
 - Selective β_3 agonists: as octopamine
 - Non-selective $\beta_1 + \beta_2 + \beta_3$ agonists: as isoprenaline
- **$\alpha + \beta$ receptor agonists:**
 - $\alpha_1 + \alpha_2 + \beta_1 + \beta_2 + \beta_3$ agonists: as adrenaline
 - $\alpha_1 + \alpha_2 + \beta_1 + \beta_3$ agonists: as NA
 - $\alpha_1 + \beta_1 + D$ agonists: as dopamine



12

Please, if possible, try to stick to the following scheme to discuss a drug or a group of drugs:

NAME of the Drug or Group

- Def.:** a few words about source and important properties.
- Classification (position):** if a group (classification), if a drug (position).
- Pharmacokinetics:** absorption, distribution, metabolism & excretion.
- Pharmacodynamics:** mechanism of action, action (therapeutic & adverse).
- Pharmacotherapeutics:** indications, contra-indications, precautions.
- Drug toxicity:** if any, manifestations & approach.
- Drug Preparations:** brand names.



13

ADRENALINE


- Def.:**

Adrenaline or epinephrine is a natural catecholamine present in adrenal medulla and some neurons in CNS.
Endogenously, it acts as a chemical transmitter at postganglionic sympathetic nerves except those of sweat glands (ACh).
It is unstable, oxidized in air or light → adrenochrome, red in color, toxic.
Stable in blood due to presence of glutathione and ascorbate; reducing agents.

- Class. (Position):** one of sympathomimetics.

- Pharmacokinetics:**

- Not effective orally
- Given locally in epistaxis
- Given by SC to lessen rate of absorption of other drugs
- Given by inhalation in bronchial asthma
- Given by intracardiac route for cardiac resuscitation
- As all catecholamines, adrenaline does NOT pass BBB.
- Neuronal uptake;
- Metabolized by MAO and COMT enzymes → excreted in urine.




14

ADRENALINE

□ Pharmacodynamics:

- M.O.A.: Adrenaline acts by direct stimulation of all subtypes of adrenoceptors ($\alpha_{1,2}$ & $\beta_{1,2,3}$).


- Local actions:
 - Skin & m.m.: vasoconstriction (α) of SC and submucosal bl.vs.
 - Eye: decongestion; decrease synthesis of aqueous humor (α) → ↓ IOP
 - Bronchi: dilation (β_2) & decongestion of bronchial mucosa (α).




Vasoconstriction

- Systemic actions:
 - CNS: anxiety (no/very mild stimulation)
 - Eye: **active mydriasis** (α_1)
 - Heart: (β_1) +ve inotropic; +ve chronotropic; +ve dromotropic → ↑ COP.
 - Bl.Vs: skin, mm, renal (α_1 mainly) → VC → ↑ TPR.
sk.m, mesenteric (β_2 mainly) → VD → ↓ TPR
coronary (β_2) → dilation
 - Bl.pr: hypertension (systolic)

- RS: Bronchodilation (β_2); decongestion of bronchial mucosa (α_1)






Mydriasis




15

ADRENALINE

- GIT: viscid salivation (α_1)
spasm of sphincters (α_1)
relaxation of the wall (β_2)
- UB: spasm of sphincter and trigone (α_1)
relaxation of the wall (*Detrusor urinae* muscle) (β_2)
urine retention
- Uterus: variable but relaxes nonpregnant uterus (β_2)
- Sk. M: VD of skeletal vessels (β_2); ↑ glycogenolysis (β_2)
anti-fatigue effect
- Anti-allergic effect: **physiological** antagonist to histamine
- Endocrine: enhances release of cortisone.
- Metabolic: hyperglycemia [↑ glycogenolysis in liver (β_2) & ↓ insulin release (α) plus cortisone-mediated > insulin release (β_2)]; ↑ lipolysis (β_1 & β_3).




16

ADRENALINE

Pharmacotherapeutics:

Indications:

- With local anesthetics except cocaine (as it inhibits uptake-1 & MAO)
- In epistaxis as haemostatic nasal pack
- In open angle glaucoma as eye drops (as prodrug Di-pivalyl epinephrine; Dipivefrine)
- Cardiac arrest
- Acute bronchial asthma
- Acute allergies and anaphylaxis
- Acute hypoglycemia



Contra-indications:

- Around fingers & toes and in circumcision
- Hypertension
- Cardiac arrhythmia, thyrotoxicosis, digitalis & volatile general anesthesia.
- MAO inhibitors

Precautions:

Should be used under medical supervision.



17


NORADRENALINE

Def.:

NA is a natural catecholamine present in all postganglionic sympathetic neurons (except sweat glands, in which transmitter is ACh), adrenal medulla (20%) and some neurons in CNS.

Pharmacology:

- **M.O.A.:** NA acts by direct NON-selective stimulation of $\alpha_{1,2}$ mainly & little $\beta_{1,3}$ but NOT β_2 .
- **Actions & Uses :** as Adrenaline without β_2 effects and applications.




ISOPRENALINE

Def.:

Synthetic catecholamine; not present in the body.

Pharmacology:

- **M.O.A.:** Isoprenaline acts by direct NON-selective stimulation of $\beta_{1,2,3}$ but NOT α receptor.
- **Actions & Uses:** as Adrenaline without α applications.



18

EPHEDRINE

Ephedrine is a NON-catecholamine alkaloid obtained either naturally from *Ephedra vulgaris* plant and/or prepared synthetically.

It is a sympathomimetic as adrenaline but with some differences:


	Epinephrine	Ephedrine
Nature	Natural catecholamine	Natural & synthetic NONcatecholamine
<u>Kinetics:</u>		
Absorption	Not effective orally	Effective orally
Distribution	CanNOT pass BBB	Pass BBB
Metabolism	Rapidly by MAO & COMT	Not metabolized
Duration	Short	Long
<u>Dynamics:</u>		
MOA	Direct	Dual
<u>Local action:</u>		
Eye	Decongestion withOUT mydriasis	Decongestion + mydriasis
Nose	Decongestion	Decongestion → rebound congestion
<u>Sympathetic actions:</u>		
Potency	Potent	Weaker
Onset	Rapid	Slower
Duration	Short	Longer
<u>CNS actions:</u>	No/Mild	Potent CNS stimulant
Uses	Acute attacks	Prophylaxis
Adverse effects	Unwanted α & β	Unwanted α & β and CNS

19

SYMPATHOLYTICS

These are the drugs which block adrenergic receptors & neurons and produce actions similar to those of sympathetic nerve inhibition.

They are classified according to their **site** of action into:



20

Alpha adrenoceptor blockers

Def.: These are the drugs which antagonize the α -effects of adrenergic drugs.

Classification:

Sub-classified according to site of action into:

A- Nonselective α -blockers

- phentolamine & tolazoline
- phenoxybenzamine

B- Selective α_1 -blockers

- prazosin, doxazosin & terazosin

C- Selective α_2 -blockers

- yohimbine

D- Other drugs with α -blocking effect

- ergot alkaloids

General uses:

- hypertension

- peripheral vascular disease



21

Ergot alkaloids

Def.: alkaloids obtained from *Ergot* which is a fungus grows on Rye.

Members: ergotamine, ergotamine and ergometrine

Pharmacodynamics:

-M.O.A.: direct blocking of α -receptors

- Actions:

- although α -blockers that should produce vasodilation, yet they have more powerful direct SPASMOGENIC action with net result of vasoconstriction, (particularly, ergotamine & ergotoxin).
- oxytocic effect (particularly ergometrine).
- HYDROGENATION of ergot leads to \uparrow α -blocking effect & \downarrow spasmogenic effect on bl.vs., e.g., dihydroergotoxine (hydergine) \rightarrow VASODILATION.
- METHYLATION of ergot leads to \uparrow spasmogenic oxytocic action on the uterus, e.g. methylegometrine.

Therapeutic uses:

- ergotamine & ergotoxin: Migraine, better taken plus caffeine (Cafergot)[®]
- ergometrine: Uterine inertia, retained placenta, postpartum hemorrhage, to help involution of the uterus & uterine prolapse.

Contra-indications:

- peripheral vascular disease
- pregnancy

- hypertension

- liver & kidney disease



22

Beta adrenoceptor blockers

Def.: These are the drugs which antagonize the β -effects of adrenergic drugs.

Classification:

According to receptor selectivity into:

A- Nonselective β -blockers

- Propranolol, Pindolol, Timolol
- Oxprenolol, Nadolol

B- Selective β_1 -blockers (Cardio-selective)

- Atenolol, Acebutolol
- Metoprolol, Bisoprolol

C- Selective β_2 -blockers

- Butoxamine

D- β -blockers with vasodilating activity

- Labetalol, Carvedilol, Nebivolol...

According to lipid solubility into:

A- Lipophilic β -blockers

- Propranolol, Oxprenolol, Metoprolol → pass BBB with CNS side actions

B- Lipophobic β -blockers

- Atenolol, Nadolol → don't pass BBB with minimal CNS effect

23

Indications:

- Angina pectoris (caused by cardiac overload).
- Cardiac tachyarrhythmia
- Thyrotoxicosis
- Hypertension
- Varices & aneurysm
- Open angle glaucoma (Timolol)
- Anxiety and panic disorders
- Prophylaxis against migraine


Contra-indications:

- Prinzmetal's angina (caused by coronary spasm or stenosis).
- Heart failure
- Diabetes mellitus
- Peripheral vascular disease
- Alone (withOUT α -blockers) in pheochromocytoma
- Sudden stop of treatment with β -blockers → severe relapse
- Hypotension
- Bronchial asthma

Precautions:

- Adjustment of doses of co-administered drugs.
- Monitoring lipid profile, glucose and K^+ levels.

24



25

Adrenergic NEURON blockers

Def.: These are the drugs which interfere with synthesis or storage or release of adrenergic neurotransmitters.

Synthesis inhibitors

Members: - alpha-methyltyrosine (metyrosine), alpha-methyl dopa (Aldomet)

Pharmacodynamics:

M.O.A.:

- alpha-methyltyrosine blocks the synthesis of NE by inhibiting tyrosine hydroxylase.
- alpha-methyl dopa is an inhibitor of aromatic L-amino acid decarboxylase, and is—like dopa itself—successively decarboxylated and hydroxylated in its side chain to form the putative "false neurotransmitter", methylnorepinephrine.

- Actions:

- Sympatholytic.

Therapeutic uses:

- alpha-methyl dopa can be used in pheochromocytoma
- alpha-methyl dopa is useful as central antihypertensive as the formed alpha-methylNE is a selective alpha₂-receptor agonist that ↓ central sympathetic outflow, ↓ release of NE & ↓ release of renin; and it is safe on the fetus during pregnancy.

26

Storage inhibitors or depletors

Member: - Reserpine (Serpasil), it is an alkaloid from *Rauwolfia serpentina* plant.

Pharmacodynamics:

M.O.A.:

- Reserpine irreversibly inhibits granular Mg⁺⁺-dependent ATPase that is responsible for granular uptake & storage of NA & dopamine. By the occurred inhibition the neurotransmitters are hydrolyzed by MAO & COMT leading to depletion of catecholamine stores within CNS & PNS.
- The same occurs for 5-HT stores.

- Actions:

- Sympatholytic giving the upper hand to parasympathetic arm.
- Major tranquilizer, due to depletion of the excitatory stores of NA & 5-HT.

Therapeutic uses:

- Hypertension
- Psychosis

Contra uses:

- Psychic depression
- Parkinsonism
- Peptic ulcer



27

Release inhibitors

Member: - Guanethidine (Ismelin), Guanadrel & Bretylium

Pharmacodynamics:

M.O.A.:

- Guanethidine acts at the sympathetic neuro-effector junction by inhibiting or interfering with the release of NE, NOT at the brain (canNOT pass BBB) or adrenal medulla.
- It is taken up by NE transporters; once inside the terminal it blocks the process of exocytosis & release of NE in response to arrival of an action potential.
- Furthermore it is being gradually concentrated in vesicles, replacing NE. This leads to a gradual depletion of NE stores in the nerve endings.

- Actions:

- Sympatholytic → AS IF → parasympathomimetic

Indications:


- Hypertension
- Glaucoma as eye drops

Contraindications:

- Pheochromocytoma
- Peptic ulcer



28



29

CHOLINERGIC RECEPTORS

Def. : Cholinoceptors are membrane bound receptors either coupled with G-proteins or with ligand-gated ion channels, specific to ACh & their antagonists.

Types:


→ **Muscarinic (M) or Peripheral cholinergic receptors:**

TYPE	LOCATION	MECHANISM	AGONIST	ANTAGONISTS
M1	Gastric parietal cells, CNS & presynaptic	G _q → ↑PLC → ↑IP ₃ & DAG → ↑Ca ⁺⁺	ACh	Atropine Pirenzepine
M2	Cardiac M., Sphincters, & presynaptic	G _i → ↓AC → ↓cAMP	ACh	Atropine Gallamine
M3	Smooth M., Exocrine G., Endothelium & CNS	G _q → ↑PLC → ↑IP ₃ & DAG → ↑Ca ⁺⁺	ACh	Atropine


→ **Nicotinic (N) or Central cholinergic receptors:**

TYPE	LOCATION	MECHANISM	AGONIST	ANTAGONISTS
N _N	Autonomic ganglia, adrenal medulla & CNS	Gated to Na ⁺ ion channel	ACh	Nicotine LD
N _M	Skeletal muscle (motor end plate)	Gated to Na ⁺ ion channel	ACh	d-Tubucurarine

30



31



32

A) Muscarinic actions:

- ↑ *Constrictor pupillae* muscle (M3) → miosis
- ↑ ciliary muscle → accommodation of the eye to near vision
- ↓ IOP via wide angle filtration
- ↑ lacrimation - conjunctival vasodilation



- ↓ S-A node → -ve chronotropic → bradycardia (M2)
- ↓ A-V node → -ve dromotropic → delays conduction to ventricles
- ↑ non-innervated M3 receptors on endothelium → release of EDRFs as NO → vasodilation → ↓TPR
- hypotension due to bradycardia and low TPR



- Bronchospasm & increased bronchial secretion (M3)



- ↑ peristalsis, ↑ secretions (M3), ↓ relax sphincters (M2) → defecation

33



- ↑ *Detrusor urinae* muscle (M3), ↓ relax sphincter (M2) → urination



- ↑ myometrium (M3)



- ↑ glandular secretions including thermoregulatory sweat glands (M3).

B) Nicotinic actions:

- Sk. M.: ↑ N_M receptor → contraction, twitches & convulsions
- Aut. Ganglia & Adr. medulla: ↑ N_N receptor > hypertension (**if alone**)

Therapeutic uses:

ACh is not used clinically as it is:

- Ineffective orally
- of short duration
- nonselective

34

Synthetic CHOLINE ESTERS

Members: METHACHOLINE, CARBACHOL & BETHANECHOL.

Def.: Synthetic quaternary amm. Compounds with the following characters:

- Lipophobic, doNOT pass BBB & distributed only extracellularly.
- Effective orally & parenterally (SC), less metabolized by ChE → longer
- With some selectivity

Dynamics, Kinetics & uses compared to ACh:

	Acetylcholine	Methacholine	Carbachol	Bethanechol
Nature	Natural	Synthetic	Synthetic	Synthetic
Metabolized by	Both ChEs, true & pseudo	True only	Not	Not
Orally	Not effective	Irregular	Complete	Complete
Duration	Short	Longer	Longer	Longer
Muscarinic actions	++++	++++	++++	++++
Nicotinic actions	++++	±	++++	Devoid
Selectivity	No	CVS	Eye, GIT, UB	GIT, UB
Therapeutic uses	Not used clinically	Tachycardia Peripheral vascular disease	Glaucoma Postoperative Paralytic ileus & urine retention	Postoperative Paralytic ileus & urine retention

35

CHOLINE ALKALOIDS

Members: MUSCARINE, ARECOLINE & PILOCARPINE.

Def.: Natural tertiary amines, NOT esters, therefore NOT metabolized by ChEs.

Muscarine:

- Alkaloid isolated from toxic Mushrooms (*Amanita muscaria*).
- NOT present endogenously
- Selective only on M-receptors and has muscarinic actions of ACh.

Arecoline:

- Alkaloid isolated from *Areca nut*.
- Has both nicotinic & muscarinic actions especially on GIT with CNS stimulation
- Uses as vermifuge & in folk medicine as memory enhancer chewing gum.

Pilocarpine:

- Alkaloid from *Pilocarpus jaborandi*.
- Has mainly muscarinic action especially on the eye & exocrine glands
- Uses:
 - Miotic eye drops for ttt of glaucoma & to remove adhesions between iris and lens alternatively with mydriatics
 - As sialagogue in ttt of xerostomia
 - As diaphoretic in ttt of fever
 - As hair tonic in promotion of hair growth (Tonoscalpine lotion)[®]



36

INDIRECT CHOLINERGIC STIMULANTS ANTICHOLINESTERASES

Def.: These are the drugs which deactivate ChEs resulting in accumulation of endogenous ACh which, in turn, produces its actions, both M & N.


Deactivation of ChEs may be **reversible** or **irreversible**; via occupation of the **anionic** or/and **esteratic** active sites of ChE.

Reversible:

- **Quaternary amm. alcohols:** as Edrophonium:
 - Attach to the anionic site of ChE
 - Not a substrate for the enzyme, so not metabolized
 - Rapidly reversible, so of short duration (about 5 min.)
- **Carbamate derivatives:** as Physo- & Neostigmine
 - Attach to both sites of ChE, anionic and esteratic
 - Esters, so they are metabolized by the enzyme
 - Duration is up to 6 hs

Irreversible:

- **Organophosphates:** as Parathion, Echothiophate,
 - Attach to the esteratic site
 - Not metabolized
 - Their effect needs re-synthesis of new ChE



37

EDROPHONIUM (Tensilon®)

- Synthetic quaternary amm. Alcohol, rapidly & reversibly deactivates ChE by attaching to its anionic site.
- Its action is more selective on skeletal muscle than other ChEs.
- Given by IV injection giving immediate action but of short duration (minutes).
- It was used in diagnosis of myasthenia gravis [but bradycardia is a major concern].

PHYSOSTIGMINE & NEOSTIGMINE

	Physostigmine (Eserine)	Neostigmine (Prostigmine)
Nature	Natural, tertiary amine alkaloid from <i>Calabar</i> beans	Synthetic, quaternary amm. compound
Kinetics	Absorbed orally, passes BBB, rapidly metabolized by ChE, short duration	Irregularly absorbed orally, cannot pass BBB, slowly metabolized by ChE, longer duration
Dynamics	Reversible anti-ChE More specific on the eye → miosis CNS stimulation	Reversible anti-ChE More specific on GIT & UB → ↑ wall, ↓ sph. Direct sk. muscle stimulant effect No CNS stimulation
Uses	As eye drops in: <ul style="list-style-type: none"> - Glaucoma - Counteract mydriatics - Alternatively with mydriatics to cut adhesions between iris & lens As IV injection in atropine poisoning	As IM, SC, PO (F < 5% of 15 mg tab) in: <ul style="list-style-type: none"> Myasthenia gravis (diagnosis & treatment) Postoperative paralytic ileus Postoperative urine retention Tachycardia As IV injection in curare poisoning

38

ORGANOPHOSPHOROUS COMPOUNDS

Def. & Members: Synthetic compounds with many applications, including:

- Insecticides as Parathion & Malathion
- Anthelmintics as Haloxon (Antinematode) & Metrifonate (Anti-Shistosoma)
- War gases as Sarin, Tabun & Soman (OBSOLETE).
- For Glaucoma as **Isoflurophate** eye ointment & **Echothiophate** eye drops.

Pharmacokinetics:

- Have high lipid solubility > rapidly absorbed from all sites; and well distributed.

Pharmacodynamics:

- They deactivate ChE by phosphorylating its esteratic site in an irreversible manner; this leads to accumulation of endogenous ACh which stimulate both M and N receptors.
- Such irreversible effect ends by re-synthesis of new ChEs (butyryl ChE needs about 3 weeks; while acetyl ChE needs about 3 months)


Ttt of organophosphate toxicity:

- Atropine 1 mg/IV every 10 minutes till mydriasis, tachycardia & dry mouth; the patient should be kept atropinized for at least 48 hs to reverse muscarinic actions.
- Nicotinic action on sk. M. is reversed by anticonvulsants as **Nembutal** or **Diazepam**.
- ChE re-activators (Oximes) which are antidotes; as **PAM** (pyridine aldoxime methylchloride; pralidoxime), **DAM** (Di-acetyl-Monoxime); they are effective orally. PAM canNOT pass BBB while others can pass reactivating **both** peripheral & central ChEs.

39

Indications of AChEs:

- Myasthenia gravis
- Glaucoma (Closed angle)
- Counteraction of mydriatics
- Alternatively with mydriatics to cut adhesions between iris & lens
- Postoperative paralytic ileus
- Postoperative urine retention
- Tachycardia
- Alzheimer's disease



Contra-indications of AChEs:

- Conditions and drugs associated with INCREASED cholinergic activity (N & M).

40

CHOLINERGIC DEPRESSANTS

→ **A. Cholinergic RECEPTOR blockers:**

→ **1. Muscarinic antagonists:**

- As atropine and its substitutes


→ **2. Nicotinic antagonists:**

- Ganglionic blockers: as Hexamethonium
- Neuromuscular blockers:
 - Competitive: as d-Tubocurarine
 - Depolarizing: as Succinylcholine

→ **B. Cholinergic NEURON blockers:**

- Drugs inhibit synthesis of ACh: as Hemicholinium
- Drugs inhibit storage of ACh: as Vesamicol
- Drugs inhibit release of ACh: as Botulinium toxin

They are used mainly for their skeletal muscle relaxant effects.



41

Muscarinic antagonists

Def.: These are the drugs which compete with ACh for its M-receptors.


Members: They are classified in TWO ways:

→ **According to nature:**

- Natural alkaloids: as Atropine, Hyoscine
- Synthetic atropine substitutes:
 - Mydriatics as Homatropine
 - Antisecretory as Pirenzepine
 - Antispasmodics as Propantheline
 - Antiasthmatics as Ipratropium
 - Antiparkinsonian as Bentrropine
 - For urinary incontinence as Oxybutynin

→ **According to selectivity:**

- Nonselective: as atropine (Block **all** M-receptors, M1-M3)
- Selective: M1 antagonist as Pirenzepine
M2 antagonist as Gallamine



42

ATROPINE

Def.: It is a natural tertiary amine alkaloid obtained from *Atropa belladonna* plant.

Pharmacokinetics:

- Well absorbed orally, parenterally & from mucous membranes
- Distributed all over the body extra- & intracellularly
- Passes BBB, so it has CNS effects
- Metabolized in the liver by atropinase-hydrolysis reaction into tropic acid & tropine base; & partly excreted unchanged in urine. Acidification of urine **increases** atropine excretion.

Pharmacodynamics:

-M.O.A.: direct blocking of M-receptors (M1-M3)

-Local actions:

- Eye:

Passive mydriatic (paralysis of *C. pupillae* m.)


Cycloplegic (paralysis of ciliary m):

- → close canal of Schlemm → ↑ IOP.

- → loss of accommodation to near vision

↓ lacrimation

- Skin & mucous membranes: local anodyne



43

- Systemic peripheral actions:

- CVS:

- Tachycardia, after initial bradycardia due to central stimulation of CIC
- ↑ A-V conduction; +ve dromotropic
- Vasodilation (secondary to overheating due to block of sweating), flushing & fever occur in large dose (atropine fever)
- Mild hypertensive

- Resp. T:

- Bronchodilation
- Dry bronchial secretion, side effect in asthma; **Ipratropium** & **Tiotropium** are better as they have less effect on bronchial secretion.

- GIT:

- ↓ salivary secretion → xerostomia
- ↓ gastric acid secretion; **Pirenzepine** & **Telenzepine** are better as they are more specific on M1 receptor.
- Antispasmodic; **Proprantheline** is better as more specific
- Spasm of sphincters → constipation

44

- UB:
 - Relax the wall
 - Spasm of sphincter & trigone
 - urine retention; **Emepromium** & **Oxybutynin** are more specific
- Skin:
 - ↓ sweat secretion (anhidrosis)
- Systemic central actions:
 - Cortex:
 - Mainly CNS **stimulant** → restlessness, excitation, hallucinations, ...
 - M.O:
 - ↑ RC (analeptic) & CIC (explains initial bradycardia)
 - ↓ VC (anti-emetic), short duration (Hyoscine is better), unlike H₁ blockers which have long duration.
 - Basal G.:
 - ↓ → anti-parkinsonian; **Benztropine** is more specific



45

Indications:

- Poisoning with cholinomimetic drugs
- Ophthalmoscopic examination
- Heart block
- Bronchial asthma
- Colic either intestinal or biliary or renal
- Diarrhoea
- Peptic ulcer
- Urinary incontinence & cystitis
- Hyperhydrosis
- Vomition & motion sickness
- Parkinsonism
- Pre-anesthetic medication, to:
 - prevent respiratory depression (↑ RC)
 - prevent aspiration pneumonia (↓ salivary & bronchial secretion)
 - protect against cardiac depression (+ve chrono- & dromotropic effects)


Contra-indications:

- # Glaucoma
- # Constipation & paralytic ileus
- # Young (FF) and old (SPE, senile prostatic enlargement) patients
- # Tachycardia
- # Hypersensitivity to atropine



46

SKELETAL MUSCLES (Somatic NS)



CNS motor neuron Somatic nerve Skeletal muscle

Skeletal muscle STIMULANTS


Def. & Members: These are drugs which stimulate skeletal muscle function and **used** in ttt of myasthenia gravis.

- They include:
 - ACh and analogues acting on N_M -receptors
 - AntiCholinesterases

} (Studied previously).

Skeletal muscle RELAXANTS

Def.: These are drugs which inhibit skeletal muscle function and **used** in ttt of epilepsy and as pre-anesthetics before surgical operations.



47

Sk. muscle relaxants are classified into:

→ **A. Central sk. muscle relaxants:**
→ **In CNS (Anti-Convulsants)**


→ **B. Peripheral sk. muscle relaxants:**

Pre

1. Drugs ↓ SYNTHESIS of ACh: as Hemicholinium
2. Drugs ↓ STORAGE of ACh: as Vesamicol
3. Drugs ↓ RELEASE of ACh: as Botulinus toxin & Mg^{++}

Post

4. Neuro-muscular blockers: subdivided into:
 - **4.1. Competitive** as Curare, Gallamine
 - **4.2. Depolarizing** as Succinylcholine
5. Direct sk. muscle relaxants: as Dantrolene; it blocks Ryanodine receptor on SR of Sk.M.



Brain

SP. C.

Axon

Acetyl-CoA + Choline

ACh

ACh stored in vesicles

Nerve terminal

ACh

SK.M.

Nm receptors

RyR

Ca^{2+}


SR

48

Neuro-Muscular blockers

<u>COMPETITIVE</u>	<u>DEPOLARIZING</u>
<ul style="list-style-type: none"> - They compete with ACh for N_M-receptors at motor end plate - They produce muscular relaxation without initial stimulation - Their effect is antagonized by Anti-ChEs - <u>Examples are:</u> <ul style="list-style-type: none"> - d-tubocurarine, Atracurium, Cis-atra..., - Duration: up to 30 min (longer) - <u>Adverse effects:</u> <ul style="list-style-type: none"> - Histamine release - Bronchospasm - Hypotension - <u>Contraindications:</u> <ul style="list-style-type: none"> - Bronchial asthma - Myasthenia gravis - With aminoglycosides & quinolones 	<ul style="list-style-type: none"> - They do NOT compete with Ach for N_M receptors - They produce <u>initial stimulation</u> due to depolarization, followed by <u>depression</u> due to persistent depolarization (partial agonists) - Their effect is potentiated by anti-ChEs - <u>Examples are:</u> <ul style="list-style-type: none"> - Succinylcholine (Suxamethonium) - Duration: up to 15 min (shorter) - <u>Adverse effects:</u> <ul style="list-style-type: none"> - Initial twitches - Muscle fatigue - Hyperthermia & Hyperkalemia - Phase-2 block - <u>Contraindications:</u> <ul style="list-style-type: none"> - Peptic ulcer - Glaucoma - PseudoChE deficiency

49



50